{"id":"alxn1850","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5314736","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALXN1850 selectively inhibits complement C3 activation within the proximal tubule of the kidney, preventing downstream complement cascade amplification and tissue damage. This targeted approach aims to preserve kidney function while minimizing systemic complement inhibition, reducing the risk of infections associated with broader complement blockade.","oneSentence":"ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:01.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"C3 glomerulopathy"},{"name":"Post-infectious glomerulonephritis"}]},"trialDetails":[{"nctId":"NCT06079281","phase":"PHASE3","title":"Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-03","conditions":"Hypophosphatasia","enrollment":124},{"nctId":"NCT06079372","phase":"PHASE3","title":"Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-04-02","conditions":"Hypophosphatasia","enrollment":43},{"nctId":"NCT06079359","phase":"PHASE3","title":"Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-05-14","conditions":"Hypophosphatasia","enrollment":30},{"nctId":"NCT04980248","phase":"PHASE1","title":"Study of ALXN1850 in Participants With Hypophosphatasia (HPP)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-09-28","conditions":"Hypophosphatasia","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALXN1850","genericName":"ALXN1850","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALXN1850 is a proximal tubule-targeted complement C3 inhibitor that reduces complement-mediated kidney damage in rare kidney diseases. Used for C3 glomerulopathy, Post-infectious glomerulonephritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}